- Home
- JRS vs KOD Comparison
JRS vs KOD Comparison
Compare JRS & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- KOD
- Stock Information
- Founded
- JRS 2001
- KOD 2009
- Country
- JRS United States
- KOD United States
- Employees
- JRS N/A
- KOD N/A
- Industry
- JRS Finance/Investors Services
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JRS Finance
- KOD Health Care
- Exchange
- JRS Nasdaq
- KOD Nasdaq
- Market Cap
- JRS 224.5M
- KOD 198.4M
- IPO Year
- JRS N/A
- KOD 2018
- Fundamental
- Price
- JRS $8.02
- KOD $10.20
- Analyst Decision
- JRS
- KOD Hold
- Analyst Count
- JRS 0
- KOD 4
- Target Price
- JRS N/A
- KOD $11.75
- AVG Volume (30 Days)
- JRS 86.6K
- KOD 673.8K
- Earning Date
- JRS 01-01-0001
- KOD 08-13-2025
- Dividend Yield
- JRS 8.87%
- KOD N/A
- EPS Growth
- JRS N/A
- KOD N/A
- EPS
- JRS N/A
- KOD N/A
- Revenue
- JRS N/A
- KOD N/A
- Revenue This Year
- JRS N/A
- KOD N/A
- Revenue Next Year
- JRS N/A
- KOD N/A
- P/E Ratio
- JRS N/A
- KOD N/A
- Revenue Growth
- JRS N/A
- KOD N/A
- 52 Week Low
- JRS $5.95
- KOD $1.92
- 52 Week High
- JRS $8.00
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- JRS 66.64
- KOD 65.75
- Support Level
- JRS $7.77
- KOD $8.77
- Resistance Level
- JRS $7.87
- KOD $11.30
- Average True Range (ATR)
- JRS 0.10
- KOD 0.99
- MACD
- JRS 0.04
- KOD 0.02
- Stochastic Oscillator
- JRS 87.36
- KOD 73.24
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.